339 related articles for article (PubMed ID: 23665398)
21. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
22. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.
Lempers VJ; van den Heuvel JJ; Russel FG; Aarnoutse RE; Burger DM; Brüggemann RJ; Koenderink JB
Antimicrob Agents Chemother; 2016 Jun; 60(6):3372-9. PubMed ID: 27001813
[TBL] [Abstract][Full Text] [Related]
24. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
[TBL] [Abstract][Full Text] [Related]
25. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.
Van Aubel RA; Smeets PH; van den Heuvel JJ; Russel FG
Am J Physiol Renal Physiol; 2005 Feb; 288(2):F327-33. PubMed ID: 15454390
[TBL] [Abstract][Full Text] [Related]
26. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
28. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
29. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology.
Mutsaers HA; Caetano-Pinto P; Seegers AE; Dankers AC; van den Broek PH; Wetzels JF; van den Brand JA; van den Heuvel LP; Hoenderop JG; Wilmer MJ; Masereeuw R
Toxicol In Vitro; 2015 Oct; 29(7):1868-77. PubMed ID: 26216510
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
31. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
32. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
33. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
34. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
35. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
36. Interactions of cyclosporin a with breast cancer resistance protein.
Xia CQ; Liu N; Miwa GT; Gan LS
Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
[TBL] [Abstract][Full Text] [Related]
37. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
38. Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
Järvinen E; Troberg J; Kidron H; Finel M
Mol Pharm; 2017 Oct; 14(10):3299-3311. PubMed ID: 28850245
[TBL] [Abstract][Full Text] [Related]
39. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
[TBL] [Abstract][Full Text] [Related]
40. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]